View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Juan Ros-Padilla
  • Juan Ros-Padilla

Faes Farma : Q3 EBITDA a touch above. FY 2024 guidance nuanced to the ...

>Improving sales momentum is partially offset by SG&A inflation - Total Q3 revenues reached € 119m (+9% y-o-y vs 9% sales growth registered in Q2), a touch ahead of our estimate and the consensus. By division, sales of traditional products in Spain posted some sequential improvement (10% y-o-y in Q3 2024 vs 4% in Q2 and 14% in Q1), reflecting the positive impact that new formats are having in Bilastine that are offsetting the price reductions (+11% in Q3 vs -2% in Q2 ...

Juan Ros-Padilla
  • Juan Ros-Padilla

Faes Farma : Q2 results a touch ahead but FY 2024 guidance maintained

>Sales lose momentum in Iberia and Animal health but the Exports save the quarter - Total Q2 revenues reached € 134m (+9% y-o-y vs 7% sales growth registered in Q1), a touch ahead of our estimate. By division, sales of traditional products in Spain posted some sequential deterioration (4% y-o-y in Q2 2024 vs 14% in Q1), reflecting a softening of momentum in Bilastine (-2% in Q2 vs +5% in Q1) and flattish Mesalazine which were partially offset by a good evolution of Ca...

Juan Ros-Padilla
  • Juan Ros-Padilla

Faes Farma : Q1 EBITDA in line. FY 2024 guidance reiterated

>Momentum mirage before the SG&A and R&D hump expected from Q2 onwards - Total Q1 2024 revenues reached € 139m (+7% y-o-y vs 4% sales growth registered in Q4), a touch ahead of our estimate. By division, sales of traditional products in Spain posted some sequential improvement (14% y-o-y in Q1 2024 vs 4% in Q4), reflecting improving momentum in Bilastine (ophthalmic and ODT versions recently launched partially offsetting the generic competition in the regular version)...

Juan Ros-Padilla
  • Juan Ros-Padilla

Faes Farma : Investor day highlights. Dull FY 2024 outlook

>FY 2024 likely to be, yet another, transition year with limited earnings growth - FY 2023 was a record year in terms of earnings, but total shareholder return was negative (-5%). The year was marked by post-patent decline in Europe of its key product Bilastine and weak trends for its animal health unit (sales -17% in Q4 2023), impacted by the lower swine livestock in Europe because of the swine flu, factors that were offset by market expansion in LatAm and the resi...

Juan Ros-Padilla
  • Juan Ros-Padilla

Faes Farma : Q4 2023 EBITDA in line, unenthusiastic FY 2023 outlook me...

>Modest sales momentum, slightly softer margins - Total Q4 2023 revenues reached € 108m (+4% y-o-y vs 4% sales growth registered in Q3), broadly in line with our estimates. By division, sales of traditional products in Spain posted some sequential deterioration yet remained in positive territory y-o-y (4% y-o-y in Q4 2023 vs 6% in Q3), reflecting improving momentum in Bilastine (ophthalmic and ODT versions recently launched partially offsetting the generic competition...

Juan Ros-Padilla
  • Juan Ros-Padilla

Faes Farma : Q3 earnings a touch below. FY 2023 outlook maintained

>Sales momentum improves slightly while margins post a modest deterioration - Q3 2023 sales reached € 107m (+5% y-o-y vs +3% in Q2 2023, +2% in Q1 2023 and +2% in Q4 2022). By division, sales of traditional products in Spain posted a material sequential improvement and returned to growth territory (+6% y-o-y vs -1% in Q2 2023, -4% in Q1 2023 and -7% in Q4 2022), reflecting higher dynamism in Bilastine (ophthalmic and ODT versions recently launched partially offsetting...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch